Studies on statin interactions demonstrated that simvastatin and lovastatin, as CYP3A4 substrates, resulted in an increased risk of myopathy when combined with inhibitors like cyclosporine A and mibefradil [42,43]. Here, CYP3A4 is linked to myopathy.